{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T21:33:55Z","timestamp":1792704835350,"version":"4.5.0"},"reference-count":170,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000404","name":"Foundation for Liver Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000404","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hepatol Int"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1007\/s12072-018-9867-9","type":"journal-article","created":{"date-parts":[[2018,5,8]],"date-time":"2018-05-08T07:47:56Z","timestamp":1525765676000},"page":"223-236","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":59,"title":["Immune checkpoint receptors: homeostatic regulators of immunity"],"prefix":"10.1007","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4974-2780","authenticated-orcid":false,"given":"Antonio","family":"Riva","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1735-8538","authenticated-orcid":false,"given":"Shilpa","family":"Chokshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,5,8]]},"reference":[{"key":"9867_CR1","unstructured":"WHO. Global status report on alcohol and health 2014. World Health Organization; 2014. ISBN 978 92 4 069276 3"},{"key":"9867_CR2","unstructured":"WHO. European status report on alcohol and health 2010. World Health Organization; 2010. ISBN 978 92 890 0206 6"},{"key":"9867_CR3","doi-asserted-by":"crossref","unstructured":"Williams R, Aspinall R, Bellis M, Camps-Walsh G, Cramp M, Dhawan A, et al. Addressing liver disease in the UK: a blueprint for attaining excellence in health care and reducing premature mortality from lifestyle issues of excess consumption of alcohol, obesity, and viral hepatitis. Lancet Lond Engl 2014;384(9958):1953\u20131997","DOI":"10.1016\/S0140-6736(14)61838-9"},{"issue":"10083","key":"9867_CR4","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.1016\/S0140-6736(16)32234-6","volume":"389","author":"R Williams","year":"2017","unstructured":"Williams R, Alexander G, Aspinall R, Bosanquet J, Camps-Walsh G, Cramp M, et al. New metrics for the Lancet Standing Commission on Liver Disease in the UK. Lancet 2017;389(10083):2053\u20132080","journal-title":"Lancet"},{"key":"9867_CR5","unstructured":"Cancer Research UK. Liver cancer statistics. Cancer Research UK. 2015. \n                    http:\/\/www.cancerresearchuk.org\/health-professional\/cancer-statistics\/statistics-by-cancer-type\/liver-cancer\n                    \n                  . Accessed 24 Jan 2018"},{"key":"9867_CR6","doi-asserted-by":"crossref","unstructured":"Cohen C, Benjamin M. Alcoholics and liver transplantation. The Ethics and Social Impact Committee of the Transplant and Health Policy Center. JAMA 1991;265(10):1299\u20131301","DOI":"10.1001\/jama.1991.03460100101033"},{"key":"9867_CR7","doi-asserted-by":"crossref","unstructured":"European Association for the Study of Liver. EASL clinical practical guidelines: management of alcoholic liver disease. J Hepatol 2012;57(2):399\u2013420","DOI":"10.1016\/j.jhep.2012.04.004"},{"key":"9867_CR8","doi-asserted-by":"crossref","unstructured":"Louvet A, Mathurin P. Alcoholic liver disease: mechanisms of injury and targeted treatment. Nat Rev Gastroenterol Hepatol 2015;12(4):231\u2013242","DOI":"10.1038\/nrgastro.2015.35"},{"key":"9867_CR9","doi-asserted-by":"crossref","unstructured":"Potts JR, Howard MR, Verma S. Recurrent severe alcoholic hepatitis: clinical characteristics and outcomes. Eur J Gastroenterol Hepatol 2013;25(6):659\u2013664","DOI":"10.1097\/MEG.0b013e32835d83d9"},{"key":"9867_CR10","doi-asserted-by":"crossref","unstructured":"Albillos A, Lario M, \u00c1lvarez-Mon M. Cirrhosis-associated immune dysfunction: Distinctive features and clinical relevance. J Hepatol 2014;61(6):1385\u20131396","DOI":"10.1016\/j.jhep.2014.08.010"},{"key":"9867_CR11","doi-asserted-by":"crossref","unstructured":"Jalan R, Fernandez J, Wiest R, Schnabl B, Moreau R, Angeli P, et al. Bacterial infections in cirrhosis: a position statement based on the EASL Special Conference 2013. J Hepatol 2014;60(6):1310\u20131324","DOI":"10.1016\/j.jhep.2014.01.024"},{"key":"9867_CR12","doi-asserted-by":"crossref","unstructured":"Bonnel AR, Bunchorntavakul C, Reddy KR. Immune dysfunction and infections in patients with cirrhosis. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc 2011;9(9):727\u2013738","DOI":"10.1016\/j.cgh.2011.02.031"},{"key":"9867_CR13","doi-asserted-by":"crossref","unstructured":"Wong F, Bernardi M, Balk R, Christman B, Moreau R, Garcia-Tsao G, et al. Sepsis in cirrhosis: report on the 7th meeting of the International Ascites Club. Gut 2005;54(5):718\u2013725","DOI":"10.1136\/gut.2004.038679"},{"key":"9867_CR14","doi-asserted-by":"crossref","unstructured":"Shawcross DL, O\u2019Grady JG. The 6-month abstinence rule in liver transplantation. Lancet 2010;376(9737):216\u2013217","DOI":"10.1016\/S0140-6736(10)60487-4"},{"key":"9867_CR15","doi-asserted-by":"crossref","unstructured":"Eggers V, Pascher A, Althoff H, Thiele S, M\u00fctze J, Selignow J, et al. Immune reactivity is more suppressed in patients with alcoholic liver disease than in patients with virus-induced cirrhosis after CRH stimulation. Alcohol Clin Exp Res 2006;30(1):140\u2013149","DOI":"10.1111\/j.1530-0277.2006.00014.x"},{"key":"9867_CR16","doi-asserted-by":"crossref","unstructured":"Louvet A, Wartel F, Castel H, Dharancy S, Hollebecque A, Canva-Delcambre V, et al. Infection in patients with severe alcoholic hepatitis treated with steroids: early response to therapy is the key factor. Gastroenterology 2009;137(2):541\u2013548","DOI":"10.1053\/j.gastro.2009.04.062"},{"key":"9867_CR17","doi-asserted-by":"crossref","unstructured":"Hartmann P, Chen W-C, Schnabl B. The intestinal microbiome and the leaky gut as therapeutic targets in alcoholic liver disease. Gastrointest Sci 2012;3:402","DOI":"10.3389\/fphys.2012.00402"},{"key":"9867_CR18","doi-asserted-by":"crossref","unstructured":"Fern\u00e1ndez J, Bert F, Nicolas-Chanoine M-H. The challenges of multi-drug-resistance in hepatology. J Hepatol 2016;65(5):1043\u20131054","DOI":"10.1016\/j.jhep.2016.08.006"},{"key":"9867_CR19","doi-asserted-by":"crossref","unstructured":"Thursz MR, Richardson P, Allison M, Austin A, Bowers M, Day CP, et al. Prednisolone or pentoxifylline for alcoholic hepatitis. N Engl J Med 2015;372(17):1619\u20131628","DOI":"10.1056\/NEJMoa1412278"},{"key":"9867_CR20","doi-asserted-by":"crossref","unstructured":"Vergis N, Atkinson SR, Knapp S, Maurice J, Allison M, Austin A, et al. In patients with severe alcoholic hepatitis, prednisolone increases susceptibility to infection and infection-related mortality, and is associated with high circulating levels of bacterial DNA. Gastroenterology 2017;152(5):1068\u20131077.e4","DOI":"10.1053\/j.gastro.2016.12.019"},{"key":"9867_CR21","doi-asserted-by":"crossref","unstructured":"Markwick LJL, Riva A, Ryan JM, Cooksley H, Palma E, Tranah TH, et al. Blockade of PD1 and TIM3 restores innate and adaptive immunity in patients with acute alcoholic hepatitis. Gastroenterology 2015;148(3):590\u2013602.e10","DOI":"10.1053\/j.gastro.2014.11.041"},{"issue":"5","key":"9867_CR22","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1136\/gutjnl-2017-314458","volume":"67","author":"A Riva","year":"2018","unstructured":"Riva A, Patel V, Kurioka A, Jeffery HC, Wright G, Tarff S, et al. Mucosa-associated invariant T cells link intestinal immunity with antibacterial immune defects in alcoholic liver disease. Gut 2018;67(5):918\u2013930","journal-title":"Gut"},{"key":"9867_CR23","doi-asserted-by":"crossref","unstructured":"Bataller R, Mandrekar P. Identifying molecular targets to improve immune function in alcoholic hepatitis. Gastroenterology 2015;148(3):498\u2013501","DOI":"10.1053\/j.gastro.2015.01.013"},{"issue":"5","key":"9867_CR24","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1136\/gutjnl-2017-315284","volume":"67","author":"B Gao","year":"2018","unstructured":"Gao B, Ma J, Xiang X. MAIT cells: a novel therapeutic target for alcoholic liver disease? Gut 2018;67(5):784\u2013786","journal-title":"Gut"},{"key":"9867_CR25","doi-asserted-by":"crossref","unstructured":"Chen L, Flies DB. Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat Rev Immunol 2013;13(4):227\u2013242","DOI":"10.1038\/nri3405"},{"key":"9867_CR26","doi-asserted-by":"crossref","unstructured":"Legat A, Speiser DE, Pircher H, Zehn D, Fuertes Marraco SA. Inhibitory receptor expression depends more dominantly on differentiation and activation than \u201cExhaustion\u201d of human CD8\u2009T cells. Front Immunol 2013;4:455","DOI":"10.3389\/fimmu.2013.00455"},{"key":"9867_CR27","doi-asserted-by":"crossref","unstructured":"Kahan SM, Wherry EJ, Zajac AJ. T cell exhaustion during persistent viral infections. Virology 2015;479\u2013480:180\u2013193","DOI":"10.1016\/j.virol.2014.12.033"},{"key":"9867_CR28","doi-asserted-by":"crossref","unstructured":"Moir S, Fauci AS. B-cell exhaustion in HIV infection: the role of immune activation. Curr Opin HIV AIDS 2014;9(5):472\u2013477","DOI":"10.1097\/COH.0000000000000092"},{"key":"9867_CR29","doi-asserted-by":"crossref","unstructured":"Boliar S, Murphy MK, Tran TC, Carnathan DG, Armstrong WS, Silvestri G, et al. B-lymphocyte dysfunction in chronic HIV-1 infection does not prevent cross-clade neutralization breadth. J Virol 2012;86(15):8031\u20138040","DOI":"10.1128\/JVI.00771-12"},{"key":"9867_CR30","doi-asserted-by":"crossref","unstructured":"Goodman A, Patel SP, Kurzrock R. PD-1-PD-L1 immune-checkpoint blockade in B-cell lymphomas. Nat Rev Clin Oncol 2017;14(4):203\u2013220","DOI":"10.1038\/nrclinonc.2016.168"},{"issue":"10","key":"9867_CR31","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.3390\/ijms18102129","volume":"18","author":"A Beldi-Ferchiou","year":"2017","unstructured":"Beldi-Ferchiou A, Caillat-Zucman S. Control of NK cell activation by immune checkpoint molecules. Int J Mol Sci. 2017;18(10):2129","journal-title":"Int J Mol Sci."},{"key":"9867_CR32","doi-asserted-by":"crossref","unstructured":"Muntasell A, Ochoa MC, Cordeiro L, Berraondo P, L\u00f3pez-D\u00edaz de Cerio A, Cabo M, et al. Targeting NK-cell checkpoints for cancer immunotherapy. Curr Opin Immunol 2017;45:73\u201381","DOI":"10.1016\/j.coi.2017.01.003"},{"key":"9867_CR33","doi-asserted-by":"crossref","unstructured":"Sipeki N, Antal-Szalmas P, Lakatos PL, Papp M. Immune dysfunction in cirrhosis. World J Gastroenterol WJG 2014;20(10):2564\u20132577","DOI":"10.3748\/wjg.v20.i10.2564"},{"issue":"11","key":"9867_CR34","doi-asserted-by":"publisher","first-page":"2413","DOI":"10.3390\/ijms18112413","volume":"18","author":"NK Patil","year":"2017","unstructured":"Patil NK, Guo Y, Luan L, Sherwood ER. Targeting immune cell checkpoints during sepsis. Int J Mol Sci 2017;18(11):2413","journal-title":"Int J Mol Sci"},{"key":"9867_CR35","doi-asserted-by":"crossref","unstructured":"Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, et al. The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA 2016;315(8):801\u2013810","DOI":"10.1001\/jama.2016.0287"},{"key":"9867_CR36","doi-asserted-by":"crossref","unstructured":"Finger LR, Pu J, Wasserman R, Vibhakar R, Louie E, Hardy RR, et al. The human PD-1 gene: complete cDNA, genomic organization, and developmentally regulated expression in B cell progenitors. Gene 1997;197(1\u20132):177\u2013187","DOI":"10.1016\/S0378-1119(97)00260-6"},{"key":"9867_CR37","doi-asserted-by":"crossref","unstructured":"Nishimura H, Nose M, Hiai H, Minato N, Honjo T. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity 1999;11(2):141\u2013151","DOI":"10.1016\/S1074-7613(00)80089-8"},{"key":"9867_CR38","doi-asserted-by":"crossref","unstructured":"Nishimura H, Okazaki T, Tanaka Y, Nakatani K, Hara M, Matsumori A, et al. Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science 2001;291(5502):319\u2013322","DOI":"10.1126\/science.291.5502.319"},{"key":"9867_CR39","doi-asserted-by":"crossref","unstructured":"Berger KN, Pu JJ. PD-1 pathway and its clinical application: a 20\u00a0year journey after discovery of the complete human PD-1 gene. Gene 2018;638:20\u201325","DOI":"10.1016\/j.gene.2017.09.050"},{"key":"9867_CR40","first-page":"4683607","volume":"2016","author":"ES Kim","year":"2016","unstructured":"Kim ES, Kim JE, Patel MA, Mangraviti A, Ruzevick J, Lim M. Immune checkpoint modulators: an emerging antiglioma armamentarium. J Immunol Res 2016;2016:4683607","journal-title":"J Immunol Res"},{"key":"9867_CR41","doi-asserted-by":"crossref","unstructured":"Parry RV, Chemnitz JM, Frauwirth KA, Lanfranco AR, Braunstein I, Kobayashi SV, et al. CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms. Mol Cell Biol 2005;25(21):9543\u20139553","DOI":"10.1128\/MCB.25.21.9543-9553.2005"},{"key":"9867_CR42","doi-asserted-by":"crossref","unstructured":"Freeman GJ, Long AJ, Iwai Y, Bourque K, Chernova T, Nishimura H, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 2000;192(7):1027\u20131034","DOI":"10.1084\/jem.192.7.1027"},{"key":"9867_CR43","doi-asserted-by":"crossref","unstructured":"Latchman Y, Wood CR, Chernova T, Chaudhary D, Borde M, Chernova I, et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol 2001;2(3):261\u2013268","DOI":"10.1038\/85330"},{"key":"9867_CR44","doi-asserted-by":"crossref","unstructured":"Petroff MG, Chen L, Phillips TA, Hunt JS. B7 family molecules: novel immunomodulators at the maternal-fetal interface. Placenta 2002;23(Suppl A):S95\u2013S101","DOI":"10.1053\/plac.2002.0813"},{"key":"9867_CR45","doi-asserted-by":"crossref","unstructured":"Spranger S, Spaapen RM, Zha Y, Williams J, Meng Y, Ha TT, et al. Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells. Sci Transl Med 2013;5(200):200ra116","DOI":"10.1126\/scitranslmed.3006504"},{"key":"9867_CR46","doi-asserted-by":"crossref","unstructured":"Liang SC, Latchman YE, Buhlmann JE, Tomczak MF, Horwitz BH, Freeman GJ, et al. Regulation of PD-1, PD-L1, and PD-L2 expression during normal and autoimmune responses. Eur J Immunol 2003;33(10):2706\u20132716","DOI":"10.1002\/eji.200324228"},{"key":"9867_CR47","doi-asserted-by":"crossref","unstructured":"Collins M, Ling V, Carreno BM. The B7 family of immune-regulatory ligands. Genome Biol 2005;6(6):223","DOI":"10.1186\/gb-2005-6-6-223"},{"key":"9867_CR48","doi-asserted-by":"crossref","unstructured":"Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 2008;26(1):677\u2013704","DOI":"10.1146\/annurev.immunol.26.021607.090331"},{"key":"9867_CR49","doi-asserted-by":"crossref","unstructured":"Azuma T, Yao S, Zhu G, Flies AS, Flies SJ, Chen L. B7-H1 is a ubiquitous antiapoptotic receptor on cancer cells. Blood 2008;111(7):3635\u20133643","DOI":"10.1182\/blood-2007-11-123141"},{"key":"9867_CR50","doi-asserted-by":"crossref","unstructured":"Eissner G, Kolch W, Scheurich P. Ligands working as receptors: reverse signaling by members of the TNF superfamily enhance the plasticity of the immune system. Cytokine Growth Factor Rev 2004;15(5):353\u2013366","DOI":"10.1016\/j.cytogfr.2004.03.011"},{"key":"9867_CR51","doi-asserted-by":"crossref","unstructured":"Munn DH, Sharma MD, Mellor AL. Ligation of B7-1\/B7-2 by human CD4\u2009+\u2009T cells triggers indoleamine 2,3-dioxygenase activity in dendritic cells. J Immunol 2004;172(7):4100\u20134110","DOI":"10.4049\/jimmunol.172.7.4100"},{"key":"9867_CR52","doi-asserted-by":"crossref","unstructured":"Butte MJ, Keir ME, Phamduy TB, Freeman GJ, Sharpe AH. PD-L1 interacts specifically with B7-1 to inhibit T cell proliferation. Immunity 2007;27(1):111\u2013122","DOI":"10.1016\/j.immuni.2007.05.016"},{"key":"9867_CR53","doi-asserted-by":"crossref","unstructured":"Park J-J, Omiya R, Matsumura Y, Sakoda Y, Kuramasu A, Augustine MM, et al. B7-H1\/CD80 interaction is required for the induction and maintenance of peripheral T-cell tolerance. Blood 2010;116(8):1291\u20131298","DOI":"10.1182\/blood-2010-01-265975"},{"key":"9867_CR54","doi-asserted-by":"crossref","unstructured":"Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012;12(4):252\u2013264","DOI":"10.1038\/nrc3239"},{"key":"9867_CR55","doi-asserted-by":"crossref","unstructured":"Said EA, Dupuy FP, Trautmann L, Zhang Y, Shi Y, El-Far M, et al. Programmed death-1-induced interleukin-10 production by monocytes impairs CD4\u2009+\u2009T cell activation during HIV infection. Nat Med 2010;16(4):452\u2013459","DOI":"10.1038\/nm.2106"},{"key":"9867_CR56","doi-asserted-by":"crossref","unstructured":"Monney L, Sabatos CA, Gaglia JL, Ryu A, Waldner H, Chernova T, et al. Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease. Nature 2002;415(6871):536\u2013541","DOI":"10.1038\/415536a"},{"key":"9867_CR57","doi-asserted-by":"crossref","unstructured":"Zhu C, Anderson AC, Schubart A, Xiong H, Imitola J, Khoury SJ, et al. The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. Nat Immunol 2005;6(12):1245\u20131252","DOI":"10.1038\/ni1271"},{"key":"9867_CR58","doi-asserted-by":"crossref","unstructured":"Hastings WD, Anderson DE, Kassam N, Koguchi K, Greenfield EA, Kent SC, et al. TIM-3 is expressed on activated human CD4\u2009+\u2009T cells and regulates Th1 and Th17 cytokines. Eur J Immunol 2009;39(9):2492\u20132501","DOI":"10.1002\/eji.200939274"},{"key":"9867_CR59","doi-asserted-by":"crossref","unstructured":"Dong J, Yang X-F, Wang L-X, Wei X, Wang A-H, Hao C-Q, et al. Modulation of Tim-3 expression by antigen-dependent and -independent factors on T cells from patients with chronic hepatitis B virus infection. Front Cell Infect Microbiol 2017;7:98","DOI":"10.3389\/fcimb.2017.00098"},{"key":"9867_CR60","doi-asserted-by":"crossref","unstructured":"Mujib S, Jones RB, Lo C, Aidarus N, Clayton K, Sakhdari A, et al. Antigen-independent induction of Tim-3 expression on human T cells by the common \u03b3-chain cytokines IL-2, IL-7, IL-15, and IL-21 is associated with proliferation and is dependent on the phosphoinositide 3-kinase pathway. J Immunol Baltim Md 1950 2012;188(8):3745\u20133756","DOI":"10.4049\/jimmunol.1102609"},{"key":"9867_CR61","unstructured":"Asakura H, Kashio Y, Nakamura K, Seki M, Dai S, Shirato Y, et al. Selective eosinophil adhesion to fibroblast via IFN-gamma-induced galectin-9. J Immunol Baltim Md 1950 2002;169(10):5912\u20135918"},{"key":"9867_CR62","doi-asserted-by":"crossref","unstructured":"Jones RB, Ndhlovu LC, Barbour JD, Sheth PM, Jha AR, Long BR, et al. Tim-3 expression defines a novel population of dysfunctional T cells with highly elevated frequencies in progressive HIV-1 infection. J Exp Med 2008;205(12):2763\u20132779","DOI":"10.1084\/jem.20081398"},{"key":"9867_CR63","doi-asserted-by":"crossref","unstructured":"Golden-Mason L, Palmer BE, Kassam N, Townshend-Bulson L, Livingston S, McMahon BJ, et al. Negative immune regulator Tim-3 is overexpressed on T cells in hepatitis C virus infection and its blockade rescues dysfunctional CD4\u2009+\u2009and CD8\u2009+\u2009T cells. J Virol 2009;83(18):9122\u20139130","DOI":"10.1128\/JVI.00639-09"},{"key":"9867_CR64","doi-asserted-by":"crossref","unstructured":"Liu Y, Gao L-F, Liang X-H, Ma C-H. Role of Tim-3 in hepatitis B virus infection: an overview. World J Gastroenterol 2016;22(7):2294\u20132303","DOI":"10.3748\/wjg.v22.i7.2294"},{"key":"9867_CR65","doi-asserted-by":"crossref","unstructured":"Fourcade J, Sun Z, Benallaoua M, Guillaume P, Luescher IF, Sander C, et al. Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8\u2009+\u2009T cell dysfunction in melanoma patients. J Exp Med 2010;207(10):2175\u20132186","DOI":"10.1084\/jem.20100637"},{"key":"9867_CR66","doi-asserted-by":"crossref","unstructured":"Sakuishi K, Apetoh L, Sullivan JM, Blazar BR, Kuchroo VK, Anderson AC. Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J Exp Med 2010;207(10):2187\u20132194","DOI":"10.1084\/jem.20100643"},{"key":"9867_CR67","doi-asserted-by":"crossref","unstructured":"Sakuishi K, Jayaraman P, Behar SM, Anderson AC, Kuchroo VK. Emerging Tim-3 functions in anti-microbial and tumor immunity. Trends Immunol 2011;32(8):345\u2013349","DOI":"10.1016\/j.it.2011.05.003"},{"key":"9867_CR68","doi-asserted-by":"crossref","unstructured":"Jin H-T, Anderson AC, Tan WG, West EE, Ha S-J, Araki K, et al. Cooperation of Tim-3 and PD-1 in CD8 T-cell exhaustion during chronic viral infection. Proc Natl Acad Sci USA 2010;107(33):14733\u201314738","DOI":"10.1073\/pnas.1009731107"},{"issue":"2","key":"9867_CR69","doi-asserted-by":"publisher","first-page":"e30852","DOI":"10.1371\/journal.pone.0030852","volume":"7","author":"L Baitsch","year":"2012","unstructured":"Baitsch L, Legat A, Barba L, Fuertes Marraco SA, Rivals J-P, Baumgaertner P, et al. Extended co-expression of inhibitory receptors by human CD8 T-cells depending on differentiation, antigen-specificity and anatomical localization. PLoS One 2012;7(2):e30852","journal-title":"PLoS One"},{"key":"9867_CR70","doi-asserted-by":"crossref","unstructured":"Ngiow SF, von Scheidt B, Akiba H, Yagita H, Teng MWL, Smyth MJ. Anti-TIM3 antibody promotes T cell IFN-\u03b3-mediated antitumor immunity and suppresses established tumors. Cancer Res 2011;71(10):3540\u20133551","DOI":"10.1158\/0008-5472.CAN-11-0096"},{"key":"9867_CR71","doi-asserted-by":"crossref","unstructured":"Sada-Ovalle I, Ch\u00e1vez-Gal\u00e1n L, Torre-Bouscoulet L, Nava-Gami\u00f1o L, Barrera L, Jayaraman P, et al. The Tim3-galectin 9 pathway induces antibacterial activity in human macrophages infected with Mycobacterium tuberculosis. J Immunol Baltim Md 1950 2012;189(12):5896\u20135902","DOI":"10.4049\/jimmunol.1200990"},{"key":"9867_CR72","doi-asserted-by":"crossref","unstructured":"Qiu Y, Chen J, Liao H, Zhang Y, Wang H, Li S, et al. Tim-3-expressing CD4\u2009+\u2009and CD8\u2009+\u2009T cells in human tuberculosis (TB) exhibit polarized effector memory phenotypes and stronger anti-TB effector functions. PLoS Pathog 2012;8(11):e1002984","DOI":"10.1371\/journal.ppat.1002984"},{"key":"9867_CR73","doi-asserted-by":"crossref","unstructured":"Jayaraman P, Sada-Ovalle I, Beladi S, Anderson AC, Dardalhon V, Hotta C, et al. Tim3 binding to galectin-9 stimulates antimicrobial immunity. J Exp Med 2010;207(11):2343\u20132354","DOI":"10.1084\/jem.20100687"},{"key":"9867_CR74","doi-asserted-by":"crossref","unstructured":"Wang X, Cao Z, Jiang J, Li Y, Dong M, Ostrowski M, et al. Elevated expression of Tim-3 on CD8 T cells correlates with disease severity of pulmonary tuberculosis. J Infect 2011;62(4):292\u2013300","DOI":"10.1016\/j.jinf.2011.02.013"},{"key":"9867_CR75","doi-asserted-by":"crossref","unstructured":"Collins AV, Brodie DW, Gilbert RJC, Iaboni A, Manso-Sancho R, Walse B, et al. The interaction properties of costimulatory molecules revisited. Immunity 2002;17(2):201\u2013210","DOI":"10.1016\/S1074-7613(02)00362-X"},{"key":"9867_CR76","doi-asserted-by":"crossref","unstructured":"Mareng\u00e8re LE, Waterhouse P, Duncan GS, Mittr\u00fccker HW, Feng GS, Mak TW. Regulation of T cell receptor signaling by tyrosine phosphatase SYP association with CTLA-4. Science 1996;272(5265):1170\u20131173","DOI":"10.1126\/science.272.5265.1170"},{"key":"9867_CR77","doi-asserted-by":"crossref","unstructured":"Chuang E, Fisher TS, Morgan RW, Robbins MD, Duerr JM, Vander Heiden MG, et al. The CD28 and CTLA-4 receptors associate with the serine\/threonine phosphatase PP2A. Immunity 2000;13(3):313\u2013322","DOI":"10.1016\/S1074-7613(00)00031-5"},{"key":"9867_CR78","doi-asserted-by":"crossref","unstructured":"Qureshi OS, Zheng Y, Nakamura K, Attridge K, Manzotti C, Schmidt EM, et al. Trans-endocytosis of CD80 and CD86: a molecular basis for the cell extrinsic function of CTLA-4. Science 2011;332(6029):600\u2013603","DOI":"10.1126\/science.1202947"},{"key":"9867_CR79","doi-asserted-by":"crossref","unstructured":"Yao S, Zhu Y, Zhu G, Augustine M, Zheng L, Goode DJ, et al. B7-h2 is a costimulatory ligand for CD28 in human. Immunity 2011;34(5):729\u2013740","DOI":"10.1016\/j.immuni.2011.03.014"},{"key":"9867_CR80","doi-asserted-by":"crossref","unstructured":"Triebel F, Jitsukawa S, Baixeras E, Roman-Roman S, Genevee C, Viegas-Pequignot E, et al. LAG-3, a novel lymphocyte activation gene closely related to CD4. J Exp Med 1990;171(5):1393\u20131405","DOI":"10.1084\/jem.171.5.1393"},{"key":"9867_CR81","doi-asserted-by":"crossref","unstructured":"Huang C-T, Workman CJ, Flies D, Pan X, Marson AL, Zhou G, et al. Role of LAG-3 in regulatory T cells. Immunity 2004;21(4):503\u2013513","DOI":"10.1016\/j.immuni.2004.08.010"},{"key":"9867_CR82","doi-asserted-by":"crossref","unstructured":"Blackburn SD, Shin H, Haining WN, Zou T, Workman CJ, Polley A, et al. Coregulation of CD8\u2009+\u2009T cell exhaustion by multiple inhibitory receptors during chronic viral infection. Nat Immunol 2009;10(1):29\u201337","DOI":"10.1038\/ni.1679"},{"key":"9867_CR83","doi-asserted-by":"crossref","unstructured":"Grosso JF, Goldberg MV, Getnet D, Bruno TC, Yen H-R, Pyle KJ, et al. Functionally distinct LAG-3 and PD-1 subsets on activated and chronically stimulated CD8 T cells. J Immunol Baltim Md 1950 2009;182(11):6659\u20136669","DOI":"10.4049\/jimmunol.0804211"},{"key":"9867_CR84","doi-asserted-by":"crossref","unstructured":"Grosso JF, Kelleher CC, Harris TJ, Maris CH, Hipkiss EL, De Marzo A, et al. LAG-3 regulates CD8\u2009+\u2009T cell accumulation and effector function in murine self- and tumor-tolerance systems. J Clin Investig 2007;117(11):3383\u20133392","DOI":"10.1172\/JCI31184"},{"key":"9867_CR85","doi-asserted-by":"crossref","unstructured":"Woo S-R, Turnis ME, Goldberg MV, Bankoti J, Selby M, Nirschl CJ, et al. Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. Cancer Res 2012;72(4):917\u2013927","DOI":"10.1158\/0008-5472.CAN-11-1620"},{"key":"9867_CR86","doi-asserted-by":"crossref","unstructured":"Barber DL, Wherry EJ, Masopust D, Zhu B, Allison JP, Sharpe AH, et al. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 2006;439(7077):682\u2013687","DOI":"10.1038\/nature04444"},{"key":"9867_CR87","doi-asserted-by":"crossref","unstructured":"Trautmann L, Janbazian L, Chomont N, Said EA, Gimmig S, Bessette B, et al. Upregulation of PD-1 expression on HIV-specific CD8\u2009+\u2009T cells leads to reversible immune dysfunction. Nat Med 2006;12(10):1198\u20131202","DOI":"10.1038\/nm1482"},{"key":"9867_CR88","doi-asserted-by":"crossref","unstructured":"Day CL, Kaufmann DE, Kiepiela P, Brown JA, Moodley ES, Reddy S, et al. PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature 2006;443(7109):350\u2013354","DOI":"10.1038\/nature05115"},{"key":"9867_CR89","doi-asserted-by":"crossref","unstructured":"Urbani S, Amadei B, Tola D, Massari M, Schivazappa S, Missale G, et al. PD-1 expression in acute hepatitis C virus (HCV) infection is associated with HCV-specific CD8 exhaustion. J Virol 2006;80(22):11398\u201311403","DOI":"10.1128\/JVI.01177-06"},{"key":"9867_CR90","doi-asserted-by":"crossref","unstructured":"Boni C, Fisicaro P, Valdatta C, Amadei B, Di Vincenzo P, Giuberti T, et al. Characterization of hepatitis B virus (HBV)-specific T-cell dysfunction in chronic HBV infection. J Virol 2007;81(8):4215\u20134225","DOI":"10.1128\/JVI.02844-06"},{"key":"9867_CR91","doi-asserted-by":"crossref","unstructured":"Penna A, Pilli M, Zerbini A, Orlandini A, Mezzadri S, Sacchelli L, et al. Dysfunction and functional restoration of HCV-specific CD8 responses in chronic hepatitis C virus infection. Hepatology 2007;45(3):588\u2013601","DOI":"10.1002\/hep.21541"},{"key":"9867_CR92","doi-asserted-by":"crossref","unstructured":"Golden-Mason L, Palmer B, Klarquist J, Mengshol JA, Castelblanco N, Rosen HR. Upregulation of PD-1 expression on circulating and intrahepatic hepatitis C virus-specific CD8\u2009+\u2009T cells associated with reversible immune dysfunction. J Virol 2007;81(17):9249\u20139258","DOI":"10.1128\/JVI.00409-07"},{"key":"9867_CR93","doi-asserted-by":"crossref","unstructured":"Evans A, Riva A, Cooksley H, Phillips S, Puranik S, Nathwani A, et al. Programmed death 1 expression during antiviral treatment of chronic hepatitis B: Impact of hepatitis B e-antigen seroconversion. Hepatol Baltim Md 2008;48(3):759\u2013769","DOI":"10.1002\/hep.22419"},{"key":"9867_CR94","doi-asserted-by":"crossref","unstructured":"Boettler T, Panther E, Bengsch B, Nazarova N, Spangenberg HC, Blum HE, et al. Expression of the interleukin-7 receptor alpha chain (CD127) on virus-specific CD8\u2009+\u2009T cells identifies functionally and phenotypically defined memory T cells during acute resolving hepatitis B virus infection. J Virol 2006;80(7):3532\u20133540","DOI":"10.1128\/JVI.80.7.3532-3540.2006"},{"key":"9867_CR95","doi-asserted-by":"crossref","unstructured":"Zou W, Chen L. Inhibitory B7-family molecules in the tumour microenvironment. Nat Rev Immunol 2008;8(6):467\u2013477","DOI":"10.1038\/nri2326"},{"key":"9867_CR96","doi-asserted-by":"crossref","unstructured":"Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 2002;8(8):793\u2013800","DOI":"10.1038\/nm730"},{"key":"9867_CR97","doi-asserted-by":"crossref","unstructured":"Iwai Y, Ishida M, Tanaka Y, Okazaki T, Honjo T, Minato N. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci USA 2002;99(19):12293\u201312297","DOI":"10.1073\/pnas.192461099"},{"key":"9867_CR98","doi-asserted-by":"crossref","unstructured":"Konishi J, Yamazaki K, Azuma M, Kinoshita I, Dosaka-Akita H, Nishimura M. B7-H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression. Clin Cancer Res Off J Am Assoc Cancer Res 2004;10(15):5094\u20135100","DOI":"10.1158\/1078-0432.CCR-04-0428"},{"key":"9867_CR99","doi-asserted-by":"crossref","unstructured":"Hamanishi J, Mandai M, Iwasaki M, Okazaki T, Tanaka Y, Yamaguchi K, et al. Programmed cell death 1 ligand 1 and tumor-infiltrating CD8\u2009+\u2009T lymphocytes are prognostic factors of human ovarian cancer. Proc Natl Acad Sci USA 2007;104(9):3360\u20133365","DOI":"10.1073\/pnas.0611533104"},{"key":"9867_CR100","doi-asserted-by":"crossref","unstructured":"Hino R, Kabashima K, Kato Y, Yagi H, Nakamura M, Honjo T, et al. Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma. Cancer 2010;116(7):1757\u20131766","DOI":"10.1002\/cncr.24899"},{"key":"9867_CR101","doi-asserted-by":"crossref","unstructured":"Parsa AT, Waldron JS, Panner A, Crane CA, Parney IF, Barry JJ, et al. Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma. Nat Med 2007;13(1):84\u201388","DOI":"10.1038\/nm1517"},{"key":"9867_CR102","doi-asserted-by":"crossref","unstructured":"Marzec M, Zhang Q, Goradia A, Raghunath PN, Liu X, Paessler M, et al. Oncogenic kinase NPM\/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1). Proc Natl Acad Sci USA 2008;105(52):20852\u201320857","DOI":"10.1073\/pnas.0810958105"},{"key":"9867_CR103","doi-asserted-by":"crossref","unstructured":"Kim J, Myers AC, Chen L, Pardoll DM, Truong-Tran Q-A, Lane AP, et al. Constitutive and inducible expression of b7 family of ligands by human airway epithelial cells. Am J Respir Cell Mol Biol 2005;33(3):280\u2013289","DOI":"10.1165\/rcmb.2004-0129OC"},{"key":"9867_CR104","doi-asserted-by":"crossref","unstructured":"Wilke CM, Wei S, Wang L, Kryczek I, Kao J, Zou W. Dual biological effects of the cytokines interleukin-10 and interferon-\u03b3. Cancer Immunol Immunother CII 2011;60(11):1529\u20131541","DOI":"10.1007\/s00262-011-1104-5"},{"key":"9867_CR105","doi-asserted-by":"crossref","unstructured":"Kaunitz GJ, Cottrell TR, Lilo M, Muthappan V, Esandrio J, Berry S, et al. Melanoma subtypes demonstrate distinct PD-L1 expression profiles. Lab Investig J Tech Methods Pathol 2017;97(9):1063\u20131071","DOI":"10.1038\/labinvest.2017.64"},{"key":"9867_CR106","doi-asserted-by":"crossref","unstructured":"Taube JM, Young GD, McMiller TL, Chen S, Salas JT, Pritchard TS, et al. Differential Expression of immune-regulatory genes associated with PD-L1 display in melanoma: implications for PD-1 pathway blockade. Clin Cancer Res Off J Am Assoc Cancer Res 2015;21(17):3969\u20133976","DOI":"10.1158\/1078-0432.CCR-15-0244"},{"key":"9867_CR107","doi-asserted-by":"crossref","unstructured":"Taube JM, Anders RA, Young GD, Xu H, Sharma R, McMiller TL, et al. Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med 2012;4(127):127ra37","DOI":"10.1126\/scitranslmed.3003689"},{"key":"9867_CR108","doi-asserted-by":"crossref","unstructured":"Memarnejadian A, Meilleur CE, Shaler CR, Khazaie K, Bennink JR, Schell TD, et al. PD-1 blockade promotes epitope spreading in anticancer CD8\u2009+\u2009T cell responses by preventing fratricidal death of subdominant clones to relieve immunodomination. J Immunol Baltim Md 1950 2017;199(9):3348\u20133359","DOI":"10.4049\/jimmunol.1700643"},{"key":"9867_CR109","doi-asserted-by":"crossref","unstructured":"Sangro B, Gomez-Martin C, de la Mata M, I\u00f1arrairaegui M, Garralda E, Barrera P, et al. A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C. J Hepatol 2013;59(1):81\u201388","DOI":"10.1016\/j.jhep.2013.02.022"},{"key":"9867_CR110","doi-asserted-by":"crossref","unstructured":"El-Khoueiry AB, Sangro B, Yau T, Crocenzi TS, Kudo M, Hsu C, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1\/2 dose escalation and expansion trial. Lancet 2017;389(10088):2492\u20132502","DOI":"10.1016\/S0140-6736(17)31046-2"},{"key":"9867_CR111","doi-asserted-by":"crossref","unstructured":"Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012;366(26):2443\u20132454","DOI":"10.1056\/NEJMoa1200690"},{"key":"9867_CR112","doi-asserted-by":"crossref","unstructured":"Brahmer JR, Tykodi SS, Chow LQM, Hwu W-J, Topalian SL, Hwu P, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012;366(26):2455\u20132465","DOI":"10.1056\/NEJMoa1200694"},{"key":"9867_CR113","doi-asserted-by":"crossref","unstructured":"Phan GQ, Yang JC, Sherry RM, Hwu P, Topalian SL, Schwartzentruber DJ, et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci USA 2003;100(14):8372\u20138377","DOI":"10.1073\/pnas.1533209100"},{"key":"9867_CR114","doi-asserted-by":"crossref","unstructured":"Downey SG, Klapper JA, Smith FO, Yang JC, Sherry RM, Royal RE, et al. Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade. Clin Cancer Res Off J Am Assoc Cancer Res 2007;13(22 Pt 1):6681\u20136688","DOI":"10.1158\/1078-0432.CCR-07-0187"},{"key":"9867_CR115","doi-asserted-by":"crossref","unstructured":"Hodi FS, Mihm MC, Soiffer RJ, Haluska FG, Butler M, Seiden MV, et al. Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Sci USA 2003;100(8):4712\u20134717","DOI":"10.1073\/pnas.0830997100"},{"key":"9867_CR116","doi-asserted-by":"crossref","unstructured":"Hodi FS, O\u2019Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363(8):711\u2013723","DOI":"10.1056\/NEJMoa1003466"},{"key":"9867_CR117","doi-asserted-by":"crossref","unstructured":"Hamid O, Robert C, Daud A, Hodi FS, Hwu W-J, Kefford R, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 2013;369(2):134\u2013144","DOI":"10.1056\/NEJMoa1305133"},{"key":"9867_CR118","doi-asserted-by":"crossref","unstructured":"Robert C, Ribas A, Wolchok JD, Hodi FS, Hamid O, Kefford R, et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet Lond Engl 2014;384(9948):1109\u20131117","DOI":"10.1016\/S0140-6736(14)60958-2"},{"key":"9867_CR119","doi-asserted-by":"crossref","unstructured":"Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc J-F, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359(4):378\u2013390","DOI":"10.1056\/NEJMoa0708857"},{"key":"9867_CR120","doi-asserted-by":"crossref","unstructured":"Kaplon H, Reichert JM. Antibodies to watch in 2018. mAbs 2018;10(2):183\u2013203","DOI":"10.1080\/19420862.2018.1415671"},{"key":"9867_CR121","doi-asserted-by":"crossref","unstructured":"Vanpouille-Box C, Lhuillier C, Bezu L, Aranda F, Yamazaki T, Kepp O, et al. Trial watch: Immune checkpoint blockers for cancer therapy. OncoImmunology 2017;6(11):e1373237","DOI":"10.1080\/2162402X.2017.1373237"},{"key":"9867_CR122","unstructured":"Home\u2014ClinicalTrials.gov. \n                    https:\/\/clinicaltrials.gov\/ct2\/home\n                    \n                  . Accessed 6 Apr 2018"},{"key":"9867_CR123","unstructured":"NCI Drug Dictionary. National Cancer Institute. \n                    https:\/\/www.cancer.gov\/publications\/dictionaries\/cancer-drug\n                    \n                  . Accessed 6 Apr 2018"},{"key":"9867_CR124","unstructured":"NCI Thesaurus. \n                    https:\/\/ncit.nci.nih.gov\/ncitbrowser\/pages\/home.jsf\n                    \n                  . Accessed 6 Apr 2018"},{"key":"9867_CR125","doi-asserted-by":"crossref","unstructured":"Shubin NJ, Monaghan SF, Ayala A. Anti-inflammatory mechanisms of sepsis. Contrib Microbiol 2011;17:108\u2013124","DOI":"10.1159\/000324024"},{"key":"9867_CR126","doi-asserted-by":"crossref","unstructured":"Adib-Conquy M, Cavaillon J-M. Compensatory anti-inflammatory response syndrome. Thromb Haemost 2009;101(1):36\u201347","DOI":"10.1160\/TH08-07-0421"},{"key":"9867_CR127","doi-asserted-by":"crossref","unstructured":"Ward NS, Casserly B, Ayala A. The compensatory anti-inflammatory response syndrome (CARS) in critically ill patients. Clin Chest Med 2008;29(4):617\u2013625 (viii)","DOI":"10.1016\/j.ccm.2008.06.010"},{"key":"9867_CR128","doi-asserted-by":"crossref","unstructured":"Gentile LF, Cuenca AG, Efron PA, Ang D, Bihorac A, McKinley BA, et al. Persistent inflammation and immunosuppression: a common syndrome and new horizon for surgical intensive care. J Trauma Acute Care Surg 2012;72(6):1491\u20131501","DOI":"10.1097\/TA.0b013e318256e000"},{"key":"9867_CR129","doi-asserted-by":"crossref","unstructured":"Binkowska AM, Michalak G, S\u0142otwi\u0144ski R. Current views on the mechanisms of immune responses to trauma and infection. Cent-Eur J Immunol 2015;40(2):206\u2013216","DOI":"10.5114\/ceji.2015.52835"},{"key":"9867_CR130","doi-asserted-by":"crossref","unstructured":"Tang BM, Huang SJ, McLean AS. Genome-wide transcription profiling of human sepsis: a systematic review. Crit Care Lond Engl 2010;14(6):R237","DOI":"10.1186\/cc9392"},{"key":"9867_CR131","doi-asserted-by":"crossref","unstructured":"Boomer JS, Green JM, Hotchkiss RS. The changing immune system in sepsis: is individualized immuno-modulatory therapy the answer? Virulence 2014;5(1):45\u201356","DOI":"10.4161\/viru.26516"},{"key":"9867_CR132","doi-asserted-by":"crossref","unstructured":"Osuchowski MF, Welch K, Siddiqui J, Remick DG. Circulating cytokine\/inhibitor profiles reshape the understanding of the SIRS\/CARS continuum in sepsis and predict mortality. J Immunol 2006;177(3):1967\u20131974","DOI":"10.4049\/jimmunol.177.3.1967"},{"key":"9867_CR133","doi-asserted-by":"crossref","unstructured":"Oberholzer A, Oberholzer C, Moldawer LL. Sepsis syndromes: understanding the role of innate and acquired immunity. Shock Augusta Ga 2001;16(2):83\u201396","DOI":"10.1097\/00024382-200116020-00001"},{"key":"9867_CR134","doi-asserted-by":"crossref","unstructured":"Lu J, Goh SJ, Tng PYL, Deng YY, Ling E-A, Moochhala S. Systemic inflammatory response following acute traumatic brain injury. Front Biosci Landmark Ed 2009;14:3795\u20133813","DOI":"10.2741\/3489"},{"key":"9867_CR135","doi-asserted-by":"crossref","unstructured":"Russell JA. Management of sepsis. N Engl J Med 2006;355(16):1699\u20131713","DOI":"10.1056\/NEJMra043632"},{"key":"9867_CR136","doi-asserted-by":"crossref","unstructured":"Hotchkiss RS, Karl IE. The pathophysiology and treatment of sepsis. N Engl J Med 2003;348(2):138\u2013150","DOI":"10.1056\/NEJMra021333"},{"key":"9867_CR137","doi-asserted-by":"crossref","unstructured":"Angus DC. The search for effective therapy for sepsis: back to the drawing board? JAMA 2011;306(23):2614\u20132615","DOI":"10.1001\/jama.2011.1853"},{"key":"9867_CR138","doi-asserted-by":"crossref","unstructured":"Cohen J, Opal S, Calandra T. Sepsis studies need new direction. Lancet Infect Dis 2012;12(7):503\u2013505","DOI":"10.1016\/S1473-3099(12)70136-6"},{"key":"9867_CR139","doi-asserted-by":"crossref","unstructured":"Brahmamdam P, Inoue S, Unsinger J, Chang KC, McDunn JE, Hotchkiss RS. Delayed administration of anti-PD-1 antibody reverses immune dysfunction and improves survival during sepsis. J Leukoc Biol 2010;88(2):233\u2013240","DOI":"10.1189\/jlb.0110037"},{"key":"9867_CR140","doi-asserted-by":"crossref","unstructured":"Goyert SM, Silver J. Editorial: PD-1, a new target for sepsis treatment: better late than never. J Leukoc Biol 2010;88(2):225\u2013226","DOI":"10.1189\/jlb.0410240"},{"issue":"1","key":"9867_CR141","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1186\/s13054-016-1301-x","volume":"20","author":"R Shao","year":"2016","unstructured":"Shao R, Fang Y, Yu H, Zhao L, Jiang Z, Li C-S. Monocyte programmed death ligand-1 expression after 3\u20134 days of sepsis is associated with risk stratification and mortality in septic patients: a prospective cohort study. Crit Care 2016;20(1):124","journal-title":"Crit Care"},{"key":"9867_CR142","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1186\/s13054-016-1370-x","volume":"20","author":"G Monneret","year":"2016","unstructured":"Monneret G, Gossez M, Venet F. Sepsis in PD-1 light. Crit Care 2016;20:186","journal-title":"Crit Care"},{"key":"9867_CR143","unstructured":"Gao D-N, Yang Z-X, Qi Q-H. Roles of PD-1, Tim-3 and CTLA-4 in immunoregulation in regulatory T cells among patients with sepsis. Int J Clin Exp Med 2015;8(10):18998\u201319005"},{"key":"9867_CR144","doi-asserted-by":"crossref","unstructured":"Boomer JS, To K, Chang KC, Takasu O, Osborne DF, Walton AH, et al. Immunosuppression in patients who die of sepsis and multiple organ failure. JAMA 2011;306(23):2594\u20132605","DOI":"10.1001\/jama.2011.1829"},{"key":"9867_CR145","doi-asserted-by":"crossref","unstructured":"Boomer JS, Shuherk-Shaffer J, Hotchkiss RS, Green JM. A prospective analysis of lymphocyte phenotype and function over the course of acute sepsis. Crit Care Lond Engl 2012;16(3):R112","DOI":"10.1186\/cc11404"},{"key":"9867_CR146","doi-asserted-by":"crossref","unstructured":"Patera AC, Drewry AM, Chang K, Beiter ER, Osborne D, Hotchkiss RS. Frontline Science: Defects in immune function in patients with sepsis are associated with PD-1 or PD-L1 expression and can be restored by antibodies targeting PD-1 or PD-L1. J Leukoc Biol 2016;100(6):1239\u20131254","DOI":"10.1189\/jlb.4HI0616-255R"},{"key":"9867_CR147","doi-asserted-by":"crossref","unstructured":"Hotchkiss RS, Monneret G, Payen D. Sepsis-induced immunosuppression: from cellular dysfunctions to immunotherapy. Nat Rev Immunol 2013;13(12):862\u2013874","DOI":"10.1038\/nri3552"},{"key":"9867_CR148","doi-asserted-by":"crossref","unstructured":"Zhu W, Bao R, Fan X, Tao T, Zhu J, Wang J, et al. PD-L1 blockade attenuated sepsis-induced liver injury in a mouse cecal ligation and puncture model. Mediators Inflamm 2013;2013:361501","DOI":"10.1155\/2013\/361501"},{"key":"9867_CR149","doi-asserted-by":"crossref","unstructured":"Lumsden AB, Henderson JM, Kutner MH. Endotoxin levels measured by a chromogenic assay in portal, hepatic and peripheral venous blood in patients with cirrhosis. Hepatol Baltim Md 1988;8(2):232\u2013236","DOI":"10.1002\/hep.1840080207"},{"key":"9867_CR150","doi-asserted-by":"crossref","unstructured":"Chen J, Wang X-M, Wu X-J, Wang Y, Zhao H, Shen B, et al. Intrahepatic levels of PD-1\/PD-L correlate with liver inflammation in chronic hepatitis B. Inflamm Res Off J Eur Histamine Res Soc Al 2011;60(1):47\u201353","DOI":"10.1007\/s00011-010-0233-1"},{"key":"9867_CR151","doi-asserted-by":"crossref","unstructured":"Zhang Y, Zhou Y, Lou J, Li J, Bo L, Zhu K, et al. PD-L1 blockade improves survival in experimental sepsis by inhibiting lymphocyte apoptosis and reversing monocyte dysfunction. Crit Care Lond Engl 2010;14(6):R220","DOI":"10.1186\/cc9354"},{"key":"9867_CR152","doi-asserted-by":"crossref","unstructured":"Yoest JM. Clinical features, predictive correlates, and pathophysiology of immune-related adverse events in immune checkpoint inhibitor treatments in cancer: a short review. ImmunoTargets Ther 2017;6:73\u201382","DOI":"10.2147\/ITT.S126227"},{"key":"9867_CR153","doi-asserted-by":"crossref","unstructured":"Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med 2018;378(2):158\u2013168","DOI":"10.1056\/NEJMra1703481"},{"key":"9867_CR154","doi-asserted-by":"crossref","unstructured":"O\u2019Donnell JS, Long GV, Scolyer RA, Teng MWL, Smyth MJ. Resistance to PD1\/PDL1 checkpoint inhibition. Cancer Treat Rev 2017;52:71\u201381","DOI":"10.1016\/j.ctrv.2016.11.007"},{"key":"9867_CR155","doi-asserted-by":"crossref","unstructured":"Benci JL, Xu B, Qiu Y, Wu TJ, Dada H, Twyman-Saint Victor C, et al. Tumor interferon signaling regulates a multigenic resistance program to immune checkpoint blockade. Cell 2016;167(6):1540\u20131554.e12","DOI":"10.1016\/j.cell.2016.11.022"},{"key":"9867_CR156","doi-asserted-by":"crossref","unstructured":"Sade-Feldman M, Jiao YJ, Chen JH, Rooney MS, Barzily-Rokni M, Eliane J-P, et al. Resistance to checkpoint blockade therapy through inactivation of antigen presentation. Nat Commun 2017;8(1):1136","DOI":"10.1038\/s41467-017-01062-w"},{"key":"9867_CR157","doi-asserted-by":"crossref","unstructured":"Gandini S, Massi D, Mandal\u00e0 M. PD-L1 expression in cancer patients receiving anti PD-1\/PD-L1 antibodies: a systematic review and meta-analysis. Crit Rev Oncol Hematol 2016;100:88\u201398","DOI":"10.1016\/j.critrevonc.2016.02.001"},{"key":"9867_CR158","doi-asserted-by":"crossref","unstructured":"Zhang T, Fan R, Shi N, Ma W. The efficacy and safety of anti-PD-1\/PD-L1 antibodies for treatment of advanced or refractory cancers: a meta-analysis. J Clin Oncol 2017;35(15_suppl):e23075\u2013e23075","DOI":"10.1200\/JCO.2017.35.15_suppl.e23075"},{"key":"9867_CR159","doi-asserted-by":"crossref","unstructured":"Maleki Vareki S, Garrig\u00f3s C, Duran I. Biomarkers of response to PD-1\/PD-L1 inhibition. Crit Rev Oncol Hematol 2017;116:116\u2013124","DOI":"10.1016\/j.critrevonc.2017.06.001"},{"key":"9867_CR160","doi-asserted-by":"crossref","unstructured":"Garg AD, Vandenberk L, Van Woensel M, Belmans J, Schaaf M, Boon L, et al. Preclinical efficacy of immune-checkpoint monotherapy does not recapitulate corresponding biomarkers-based clinical predictions in glioblastoma. Oncoimmunology 2017;6(4):e1295903","DOI":"10.1080\/2162402X.2017.1295903"},{"key":"9867_CR161","doi-asserted-by":"crossref","unstructured":"Zhu X, Lang J. Soluble PD-1 and PD-L1: predictive and prognostic significance in cancer. Oncotarget 2017;8(57):97671\u201397682","DOI":"10.18632\/oncotarget.18311"},{"key":"9867_CR162","doi-asserted-by":"crossref","unstructured":"Li YM, Shi YY, Li Y, Yan L, Tang JT, Bai YJ, et al. Soluble Tim-3 and Gal-9 are associated with renal allograft dysfunction in kidney transplant recipients: a cross-sectional study. Int Immunopharmacol 2018;55:330\u2013335","DOI":"10.1016\/j.intimp.2018.01.008"},{"key":"9867_CR163","doi-asserted-by":"crossref","unstructured":"Chen D, Peng W, Jiang H, Yang H, Wu J, Wang H, et al. Noninvasive detection of acute renal allograft rejection by measurement of soluble Tim-3 in urine. Mol Med Rep 2017;16(1):915\u2013921","DOI":"10.3892\/mmr.2017.6670"},{"key":"9867_CR164","doi-asserted-by":"crossref","unstructured":"Dahal LN, Basu N, Youssef H, Khanolkar RC, Barker RN, Erwig LP, et al. Immunoregulatory soluble CTLA-4 modifies effector T-cell responses in systemic lupus erythematosus. Arthritis Res Ther 2016;18:180","DOI":"10.1186\/s13075-016-1075-1"},{"key":"9867_CR165","doi-asserted-by":"crossref","unstructured":"Ren F, Li J, Jiang X, Xiao K, Zhang D, Zhao Z, et al. Plasma soluble Tim-3 emerges as an inhibitor in sepsis: sepsis contrary to membrane Tim-3 on monocytes. Tissue Antigens 2015;86(5):325\u2013332","DOI":"10.1111\/tan.12653"},{"key":"9867_CR166","doi-asserted-by":"crossref","unstructured":"Simone R, Pesce G, Antola P, Rumbullaku M, Bagnasco M, Bizzaro N, et al. The soluble form of CTLA-4 from serum of patients with autoimmune diseases regulates T-cell responses. BioMed Res Int 2014;2014:215763","DOI":"10.1155\/2014\/215763"},{"key":"9867_CR167","doi-asserted-by":"crossref","unstructured":"Casati C, Camisaschi C, Rini F, Arienti F, Rivoltini L, Triebel F, et al. Soluble human LAG-3 molecule amplifies the in vitro generation of type 1 tumor-specific immunity. Cancer Res 2006;66(8):4450\u20134460","DOI":"10.1158\/0008-5472.CAN-05-2728"},{"key":"9867_CR168","doi-asserted-by":"crossref","unstructured":"Horn LA, Long TM, Atkinson R, Clements V, Ostrand-Rosenberg S. Soluble CD80 protein delays tumor growth and promotes tumor-infiltrating lymphocytes. Cancer Immunol Res 2018;6(1):59\u201368","DOI":"10.1158\/2326-6066.CIR-17-0026"},{"key":"9867_CR169","doi-asserted-by":"crossref","unstructured":"Haile ST, Horn LA, Ostrand-Rosenberg S. A soluble form of CD80 enhances antitumor immunity by neutralizing programmed death ligand-1 and simultaneously providing costimulation. Cancer Immunol Res 2014;2(7):610\u2013615","DOI":"10.1158\/2326-6066.CIR-13-0204"},{"key":"9867_CR170","doi-asserted-by":"publisher","first-page":"S810","DOI":"10.1016\/S0168-8278(18)31892-0","volume":"68","author":"A Riva","year":"2018","unstructured":"Riva A, Adams H, Patel V, Azarian S, Wright G, Tarff S, et al. The TIM3-Gal9 immune checkpoint axis is inter-linked with severity of Alcoholic Liver Disease. J Hepatol 2018;68:S810\u2013S811","journal-title":"J Hepatol"}],"container-title":["Hepatology International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12072-018-9867-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-018-9867-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-018-9867-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,7]],"date-time":"2019-05-07T19:52:27Z","timestamp":1557258747000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12072-018-9867-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5]]},"references-count":170,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["9867"],"URL":"https:\/\/doi.org\/10.1007\/s12072-018-9867-9","relation":{},"ISSN":["1936-0533","1936-0541"],"issn-type":[{"value":"1936-0533","type":"print"},{"value":"1936-0541","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5]]},"assertion":[{"value":"5 February 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"We have no conflict of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}